Department of Bioinformatics, Semmelweis University, Tüzoltó u. 7-9, 1094, Budapest, Hungary.
TTK Momentum Cancer Biomarker Research Group, Budapest, Hungary.
Sci Rep. 2021 Mar 15;11(1):6047. doi: 10.1038/s41598-021-84787-5.
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan-Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E-16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E-10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E-12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E-10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E-05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E-07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E-07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E-05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.
癌症标志性基因负责恶性转化和进展的最基本表型特征。在这项研究中,我们的目的是评估已建立的癌症标志性基因在多种不同癌症类型中的预后效应。从 TCGA 存储库中获取了 26 种不同肿瘤类型的 RNA-seq HTSeq 计数和生存数据。使用 DESeq 进行归一化。使用 Cox 比例风险回归计算基因表达与生存之间的相关性,并通过绘制 Kaplan-Meier 生存图进行计算。使用错误发现率校正多重假设检验。与基因组不稳定性和侵袭相关的基因-signature 在大多数个体癌症类型中均具有显著意义。甲状腺和神经胶质瘤与标志性基因无关(分别有 61 个和 54 个基因显著),而肾透明细胞癌和低级别神经胶质瘤则具有最多的预后变化(分别有 403 个和 419 个基因显著)。具有最高显著意义的八个基因包括 BRCA1(基因组不稳定性,HR 4.26,p < 1E-16)、RUNX1(维持增殖信号,HR 2.96,p = 3.1E-10)和 SERPINE1(诱导血管生成,HR 3.36,p = 1.5E-12)在低级别神经胶质瘤中,CDK1(细胞死亡抵抗,HR = 5.67,p = 2.1E-10)在肾乳头癌中,E2F1(肿瘤抑制因子,HR 0.38,p = 2.4E-05)和 EREG(使复制永生,HR 3.23,p = 2.1E-07)在宫颈癌中,FBP1(细胞能量失调,HR 0.45,p = 2.8E-07)在肾透明细胞癌中,MYC(侵袭和转移,HR 1.81,p = 5.8E-05)在膀胱癌中。当我们将癌症标志性基因与生存相关联时,我们观察到了出乎意料的异质性和组织特异性。这些结果将有助于为不同类型的实体瘤的未来靶向治疗开发提供优先级。